

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

NCT05942625

Status	RECRUITING
Phase	Phase 1
Sponsor	Hansoh BioMedical R&D Company
Enrollment	84 participants

Key Eligibility Criteria

Inclusion (3)

- Healthy male or female subjects between the ages of 18-45 years
- Have no reproductive potential; or agree to use a highly effective method of contraception, and refrain from donating sperm or eggs during the study period and for at least 6 months after last dosing
- Have signed the informed consent form approved by the IRB

Exclusion (7)

- History or evidence of clinically significant cardiovascular, pulmonary, endocrine, gastrointestinal, psychiatric, neurologic, hematological or metabolic diseases, especially those conditions that interfere with absorption, metabolism and/or excretion of the study drug, determined by the investigator
- Have a clinically significant infection currently or within past 30 days, or have a history of active tuberculosis; or have positive screening test for infectious disease, including tuberculosis, viral hepatitis, AIDS and syphilis
- Have a history of or current allergic disease
- Have a history of drug or alcohol abuse or currently positive test result(s) for alcohol or drugs of abuse
- Smokers smoked ≥ 5 cigarettes per day within past 3 months or have a positive test result for nicotine
- ... and 2 more (see full listing online)

Locations (1 total)

Zhongda Hospital, Affiliated to Southeast University, Nanjing, Jiangsu, China